Novel colchicine derivatives and their anti-cancer activity

Lorelei Johnson, Ing Swie Goping, Aja Rieger, Jonathan Y. Mane, Torin Huzil, Asok Banerjee, Richard Luduena, Bashar Hassani, Philip Winter, Jack A. Tuszynski

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

In this paper we provide an overview of the status of various colchicine derivatives in preclinical development with special focus on their anti-cancer activity. We discuss several groups of compounds that have been designed to differentially bind with specific affinities for tubulin β isotypes, especially in regard to βIII, which is commonly over-expressed in cancer. Computational prediction, protein-based and cell-based assays are summarized as well as some animal tests conducted on these compounds. It is concluded that an untapped potential exists for exploiting the colchicine scaffold as a pharmacophore with the possibility of increasing its affinity for tubulin isotypes over-expressed in cancer and decreasing it for normal cells thereby widening the therapeutic window.

Original languageEnglish (US)
Pages (from-to)2538-2558
Number of pages21
JournalCurrent Topics in Medicinal Chemistry
Volume17
Issue number22
DOIs
StatePublished - Sep 1 2017

Fingerprint

Colchicine
Tubulin
Neoplasms
Proteins
Therapeutics

Keywords

  • Animal tests
  • Anti-cancer
  • Colchicine Scaffold
  • Pharmacophore
  • Tubulin β isotypes

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Johnson, L., Goping, I. S., Rieger, A., Mane, J. Y., Huzil, T., Banerjee, A., ... Tuszynski, J. A. (2017). Novel colchicine derivatives and their anti-cancer activity. Current Topics in Medicinal Chemistry, 17(22), 2538-2558. https://doi.org/10.2174/1568026617666170104143618

Novel colchicine derivatives and their anti-cancer activity. / Johnson, Lorelei; Goping, Ing Swie; Rieger, Aja; Mane, Jonathan Y.; Huzil, Torin; Banerjee, Asok; Luduena, Richard; Hassani, Bashar; Winter, Philip; Tuszynski, Jack A.

In: Current Topics in Medicinal Chemistry, Vol. 17, No. 22, 01.09.2017, p. 2538-2558.

Research output: Contribution to journalReview article

Johnson, L, Goping, IS, Rieger, A, Mane, JY, Huzil, T, Banerjee, A, Luduena, R, Hassani, B, Winter, P & Tuszynski, JA 2017, 'Novel colchicine derivatives and their anti-cancer activity', Current Topics in Medicinal Chemistry, vol. 17, no. 22, pp. 2538-2558. https://doi.org/10.2174/1568026617666170104143618
Johnson L, Goping IS, Rieger A, Mane JY, Huzil T, Banerjee A et al. Novel colchicine derivatives and their anti-cancer activity. Current Topics in Medicinal Chemistry. 2017 Sep 1;17(22):2538-2558. https://doi.org/10.2174/1568026617666170104143618
Johnson, Lorelei ; Goping, Ing Swie ; Rieger, Aja ; Mane, Jonathan Y. ; Huzil, Torin ; Banerjee, Asok ; Luduena, Richard ; Hassani, Bashar ; Winter, Philip ; Tuszynski, Jack A. / Novel colchicine derivatives and their anti-cancer activity. In: Current Topics in Medicinal Chemistry. 2017 ; Vol. 17, No. 22. pp. 2538-2558.
@article{c434e12e9b9e4cf58101ad891b07bb38,
title = "Novel colchicine derivatives and their anti-cancer activity",
abstract = "In this paper we provide an overview of the status of various colchicine derivatives in preclinical development with special focus on their anti-cancer activity. We discuss several groups of compounds that have been designed to differentially bind with specific affinities for tubulin β isotypes, especially in regard to βIII, which is commonly over-expressed in cancer. Computational prediction, protein-based and cell-based assays are summarized as well as some animal tests conducted on these compounds. It is concluded that an untapped potential exists for exploiting the colchicine scaffold as a pharmacophore with the possibility of increasing its affinity for tubulin isotypes over-expressed in cancer and decreasing it for normal cells thereby widening the therapeutic window.",
keywords = "Animal tests, Anti-cancer, Colchicine Scaffold, Pharmacophore, Tubulin β isotypes",
author = "Lorelei Johnson and Goping, {Ing Swie} and Aja Rieger and Mane, {Jonathan Y.} and Torin Huzil and Asok Banerjee and Richard Luduena and Bashar Hassani and Philip Winter and Tuszynski, {Jack A.}",
year = "2017",
month = "9",
day = "1",
doi = "10.2174/1568026617666170104143618",
language = "English (US)",
volume = "17",
pages = "2538--2558",
journal = "Current Topics in Medicinal Chemistry",
issn = "1568-0266",
publisher = "Bentham Science Publishers B.V.",
number = "22",

}

TY - JOUR

T1 - Novel colchicine derivatives and their anti-cancer activity

AU - Johnson, Lorelei

AU - Goping, Ing Swie

AU - Rieger, Aja

AU - Mane, Jonathan Y.

AU - Huzil, Torin

AU - Banerjee, Asok

AU - Luduena, Richard

AU - Hassani, Bashar

AU - Winter, Philip

AU - Tuszynski, Jack A.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - In this paper we provide an overview of the status of various colchicine derivatives in preclinical development with special focus on their anti-cancer activity. We discuss several groups of compounds that have been designed to differentially bind with specific affinities for tubulin β isotypes, especially in regard to βIII, which is commonly over-expressed in cancer. Computational prediction, protein-based and cell-based assays are summarized as well as some animal tests conducted on these compounds. It is concluded that an untapped potential exists for exploiting the colchicine scaffold as a pharmacophore with the possibility of increasing its affinity for tubulin isotypes over-expressed in cancer and decreasing it for normal cells thereby widening the therapeutic window.

AB - In this paper we provide an overview of the status of various colchicine derivatives in preclinical development with special focus on their anti-cancer activity. We discuss several groups of compounds that have been designed to differentially bind with specific affinities for tubulin β isotypes, especially in regard to βIII, which is commonly over-expressed in cancer. Computational prediction, protein-based and cell-based assays are summarized as well as some animal tests conducted on these compounds. It is concluded that an untapped potential exists for exploiting the colchicine scaffold as a pharmacophore with the possibility of increasing its affinity for tubulin isotypes over-expressed in cancer and decreasing it for normal cells thereby widening the therapeutic window.

KW - Animal tests

KW - Anti-cancer

KW - Colchicine Scaffold

KW - Pharmacophore

KW - Tubulin β isotypes

UR - http://www.scopus.com/inward/record.url?scp=85026458059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026458059&partnerID=8YFLogxK

U2 - 10.2174/1568026617666170104143618

DO - 10.2174/1568026617666170104143618

M3 - Review article

C2 - 28056740

AN - SCOPUS:85026458059

VL - 17

SP - 2538

EP - 2558

JO - Current Topics in Medicinal Chemistry

JF - Current Topics in Medicinal Chemistry

SN - 1568-0266

IS - 22

ER -